Tags

Type your tag names separated by a space and hit enter

The acceptance to heterologous booster vaccination of COVID-19 vaccine among HCWs and targeted population: A cross-sectional study in central China.
Front Public Health. 2022; 10:943876.FP

Abstract

Background

There are few studies reported on the acceptance of heterologous booster vaccination for the COVID-19 vaccine among healthcare workers (HCWs) and the general population. We aimed to address that gap and explore determinant factors of acceptance of the heterologous booster vaccination.

Methods

We conducted a cross-sectional study to examine the prevalence and determinant factors of the acceptance of heterologous booster vaccination for the COVID-19 vaccine among HCWs and the targeted population.

Results

A total of 364 HCWs and 1,898 targeted populations were investigated in our study. 76.4% HCWs would recommend heterologous booster vaccination to their patients and 59.8% targeted population endorsed a clear willingness to receive this strategy. Compared with the adenoviral vector vaccine (AD5-nCOV), recombinant protein vaccine (ZF2001) was more preferred by HCWs (79.1%) and the targeted population (72.0%) as a heterologous booster vaccine. HCWs who did not work in the vaccination clinics were more likely to recommend heterologous booster vaccination (OR = 3.3, CI: 1.5-7.3). The targeted population aged 18-59 years (OR = 1.5, 95% CI:1.1-2.3), had a positive attitude toward COVID-19 vaccination (OR = 3.8, 95% CI: 1.7-8.6), had confidence in the safety of COVID-19 vaccines (OR = 6.6, 95% CI: 4.2-10.2), followed the recommendation of HCWs (OR = 33.6, 95% CI: 22.0-51.2), took initiative in collecting booster shots information (OR = 2.1, 95% CI: 1.5-3.0), and were familiar with the heterologous strategy (OR = 1.9, 95% CI: 1.1-3.1) were more likely to choose heterologous booster vaccination. The history of side effects of inactivated COVID-19 vaccine was a negative factor in choosing heterologous booster vaccination (OR = 0.4, 95% CI: 0.4-1.0).

Conclusions

The heterologous booster vaccination strategy on the COVID-19 vaccine could be widely accepted among HCWs, whereas its acceptance among targeted population was only moderate. Public authorities should make efforts to communicate the public about the effectiveness and safety of the heterologous booster vaccination which could help increase their willingness to get vaccinated.

Authors+Show Affiliations

Department of Epidemiology and Health Statistics, School of Public Health, Anhui Medical University, Hefei, China. Department of Expanded Program on Immunization, Lu'an Municipal Center for Disease Control and Prevention, Lu'an, China.Department of Expanded Program on Immunization, Lu'an Municipal Center for Disease Control and Prevention, Lu'an, China. Department of Health Inspection and Quarantine, School of Public Health, Anhui Medical University, Hefei, China.Department of Expanded Program on Immunization, Lu'an Municipal Center for Disease Control and Prevention, Lu'an, China.Department of Expanded Program on Immunization, Lu'an Municipal Center for Disease Control and Prevention, Lu'an, China.Department of Nutrition and Food Hygiene, School of Public Health, Anhui Medical University, Hefei, China.Department of Preventive Medicine, School of Public Health, Bengbu Medical College, Bengbu, China.Department of Epidemiology and Health Statistics, School of Public Health, Anhui Medical University, Hefei, China.Department of Epidemiology and Health Statistics, School of Public Health, Anhui Medical University, Hefei, China.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

35979461

Citation

Qin, Wei, et al. "The Acceptance to Heterologous Booster Vaccination of COVID-19 Vaccine Among HCWs and Targeted Population: a Cross-sectional Study in Central China." Frontiers in Public Health, vol. 10, 2022, p. 943876.
Qin W, Zhang X, Wang Y, et al. The acceptance to heterologous booster vaccination of COVID-19 vaccine among HCWs and targeted population: A cross-sectional study in central China. Front Public Health. 2022;10:943876.
Qin, W., Zhang, X., Wang, Y., Pan, F., Cheng, K., Huang, F., Song, J., & Su, H. (2022). The acceptance to heterologous booster vaccination of COVID-19 vaccine among HCWs and targeted population: A cross-sectional study in central China. Frontiers in Public Health, 10, 943876. https://doi.org/10.3389/fpubh.2022.943876
Qin W, et al. The Acceptance to Heterologous Booster Vaccination of COVID-19 Vaccine Among HCWs and Targeted Population: a Cross-sectional Study in Central China. Front Public Health. 2022;10:943876. PubMed PMID: 35979461.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The acceptance to heterologous booster vaccination of COVID-19 vaccine among HCWs and targeted population: A cross-sectional study in central China. AU - Qin,Wei, AU - Zhang,Xiaqing, AU - Wang,Yao, AU - Pan,Fan, AU - Cheng,Kai, AU - Huang,Fangfang, AU - Song,Jian, AU - Su,Hong, Y1 - 2022/08/01/ PY - 2022/05/14/received PY - 2022/07/07/accepted PY - 2022/8/18/entrez PY - 2022/8/19/pubmed PY - 2022/8/20/medline KW - COVID-19 KW - acceptance KW - healthcare workers (HCWs) KW - heterologous booster vaccination KW - willingness SP - 943876 EP - 943876 JF - Frontiers in public health JO - Front Public Health VL - 10 N2 - Background: There are few studies reported on the acceptance of heterologous booster vaccination for the COVID-19 vaccine among healthcare workers (HCWs) and the general population. We aimed to address that gap and explore determinant factors of acceptance of the heterologous booster vaccination. Methods: We conducted a cross-sectional study to examine the prevalence and determinant factors of the acceptance of heterologous booster vaccination for the COVID-19 vaccine among HCWs and the targeted population. Results: A total of 364 HCWs and 1,898 targeted populations were investigated in our study. 76.4% HCWs would recommend heterologous booster vaccination to their patients and 59.8% targeted population endorsed a clear willingness to receive this strategy. Compared with the adenoviral vector vaccine (AD5-nCOV), recombinant protein vaccine (ZF2001) was more preferred by HCWs (79.1%) and the targeted population (72.0%) as a heterologous booster vaccine. HCWs who did not work in the vaccination clinics were more likely to recommend heterologous booster vaccination (OR = 3.3, CI: 1.5-7.3). The targeted population aged 18-59 years (OR = 1.5, 95% CI:1.1-2.3), had a positive attitude toward COVID-19 vaccination (OR = 3.8, 95% CI: 1.7-8.6), had confidence in the safety of COVID-19 vaccines (OR = 6.6, 95% CI: 4.2-10.2), followed the recommendation of HCWs (OR = 33.6, 95% CI: 22.0-51.2), took initiative in collecting booster shots information (OR = 2.1, 95% CI: 1.5-3.0), and were familiar with the heterologous strategy (OR = 1.9, 95% CI: 1.1-3.1) were more likely to choose heterologous booster vaccination. The history of side effects of inactivated COVID-19 vaccine was a negative factor in choosing heterologous booster vaccination (OR = 0.4, 95% CI: 0.4-1.0). Conclusions: The heterologous booster vaccination strategy on the COVID-19 vaccine could be widely accepted among HCWs, whereas its acceptance among targeted population was only moderate. Public authorities should make efforts to communicate the public about the effectiveness and safety of the heterologous booster vaccination which could help increase their willingness to get vaccinated. SN - 2296-2565 UR - https://www.unboundmedicine.com/medline/citation/35979461/The_acceptance_to_heterologous_booster_vaccination_of_COVID_19_vaccine_among_HCWs_and_targeted_population:_A_cross_sectional_study_in_central_China_ DB - PRIME DP - Unbound Medicine ER -